Why it matters: Going forward, management expects substantial growth opportunities in FY18, and they have provided a financial guidance of $20 million in billings for FY18 and a year-end run rate of at least $25 million. Two analysts have buy ratings on CATS. Their target prices: $7.00 and $5.30.

Key quote: Terren Peizer, Chairman and CEO of CATS: “Catasys seeks to improve the health of insured members and subsequently lower costs for our insurance partners. Lowering the high costs to major health plans is the primary component of Catasys’ investment thesis.”

The back story: With its OnTrak solution, Catasys, Inc. improves member health while reducing inpatient and emergency-room utilization, driving a reduction of more than 50% in enrolled health insurers’ costs. OnTrak is currently available in 19 states to members of several leading health plans, including six of the nation’s largest plans.

The Isodiol deal allows Level Brands to realize the potential for cross-promotion with the brands it manages, Ireland said.  

“We believe there are many opportunities for deals of this significance,” Ireland said, promising to “maximize [such deals] over the next three to five years.”

A branding and marketing company, Level Brands has no CapEx or R&D costs, and its margins consistently approach 80%. The company has no debt, Ireland said.

Why it matters: The video encapsulates the strategy and goals of Level Brands, a company that went public in November 2017. Ireland’s words further the effort by Level Brands to increase awareness of what Level Brands believes is a winning formula.

Key quote: Management has “the infrastructure, know-how, and team to grow Level Brands into a powerful business.” — Kathy Ireland, Chief Brand Strategist and Chairman Emeritus, Level Brands, Inc.

The back story: Level Brands strives to maximize the value of brands through entry into licensing agreements with partners that are responsible for the design, manufacture, and distribution of licensed products. In addition, Level Brands seeks to secure strategic licenses and joint-venture partnerships for their brands, as well as to grow their portfolio of brands through strategic acquisitions.

Why it matters: The results demonstrated excellent safety and tolerability and have spurred Immuron management to take their lead drug candidate, IMM-124E, to Phase 2 proof-of-principle clinical trials.  

The top-line results have also added substantial share value. In the wake of the results, the market cap of IMRN surged 67%, from $27 million to $45 million. This is in keeping with other successes by similar companies in similar trials. For example, Intercept Pharmaceuticals had positive Phase 2 results for NASH, leading to an increase in market cap from $1.5 billion to $6.6 billion.

In March 2018, the Company secured $5.1 million in a capital-raise in a private placement with a large U.S. institutional investment fund. The capital-raise provides stability to the Company.

Back Story: Immuron's IMM-124E is in three Phase 2 clinical trials for NASH, alcoholic steatohepatitis (ASH), and pediatric non-alcoholic fatty liver disease (NAFLD). NASH therapies are estimated to become a $40 billion global market by 2025, and significant valuations have been afforded to companies in Phase 2 trials for NASH. Companies such as Galectin Therapeutics ($136.6 million), Conatus Pharmaceuticals ($171.3 million), and Genfit SA ($727.9 million), are in Phase 2 trials for NASH and have valuations higher than Immuron.

He most recently served as Controller at Emerging Power, Inc., a custom designer of portable power solutions and standard-sized battery packs for various applications including OEM, Government Agencies, Military, Aerospace and Industrial.

Back Story: MamaMancini has significant growth potential for its specialty food product lines of authentic home-style all-natural Italian meatballs, meat loaf, stuffed pepper and pasta (lasagna) dishes.

The Company has successfully launched 12 new products on QVC since June 2015, and its distribution channel has grown to over 12,200 U.S. supermarkets, capturing 30% of market share.

The Company's recent acquisition of Joseph Epstein Foods Enterprise, the sole manufacturer of MamaMancini's products, is expected to add beneficial synergies to business operations.

The Company has been cumulatively profitable since July 31, 2016. 3QFY17 was another record quarter of revenue, up 61% YOY to $7.35 million

Key Quote: “We anticipate seeing more of this activity during 2018.” – Roger Ponder, CEO

What’s Next? With favorable industry trends underpinning its core telecom-services business, it’s likely we’ll see a steady flow of new contract-win announcements in the months ahead. Right now, the stock trades for a market cap of under $3 million – less than the sales the company generated in the first two months of the year. As more investors learn of SGSI, the shares are likely to begin reflecting a much better valuation, creating a big win for those accumulating shares at current levels.

Key Quote: “We are thrilled to launch and deliver VIE to them [esports fans] at this great time for esports.” – Grant Johnson, CEO

What’s Next? In preparation for the launch of VIE, at gamescom 2017 last fall the Company secured a roster of more than 60 affiliate marketers. With VIE now live, we expect the onboarding process to get into full swing. The audience reach of these affiliates alone is estimated at more than 250 million esports viewers. Capturing even a fraction of that on its platform could lead to rapid revenue growth for GMBL.